ADVANZ PHARMA Corp
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ADVANZ PHARMA Corp
Concizumab, Elranatamab & Talquetamab Among New EU Filings At EMA
The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.
Advanz Agrees Multi-Market Omalizumab Deal With Alvotech
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.
Generics And Biosimilars Industry Reshaped By Transformations
The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.
Advanz Zeroes In On Innovative Assets And M&A
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.